Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11309239,S/R ratios,"In serum, the S/R ratios in the groups treated with 10, 20, or 100 mg kg(-1) day(-1) were 0.94, 0.83, and 0.34, respectively.",In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11309239/),,0.94,852,DB00215,Citalopram
,11309239,S/R ratios,"In serum, the S/R ratios in the groups treated with 10, 20, or 100 mg kg(-1) day(-1) were 0.94, 0.83, and 0.34, respectively.",In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11309239/),,0.83,853,DB00215,Citalopram
,11309239,S/R ratios,"In serum, the S/R ratios in the groups treated with 10, 20, or 100 mg kg(-1) day(-1) were 0.94, 0.83, and 0.34, respectively.",In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11309239/),,0.34,854,DB00215,Citalopram
,19710642,area under plasma concentration-time curve extrapolated to infinity (AUC(0-infinity)),The median area under plasma concentration-time curve extrapolated to infinity (AUC(0-infinity)) of (+)-M1 was 2.75 micromol/l.h after placebo pretreatment compared with 1.95 micromol/l.h after escitalopram (P = 0.0027).,Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19710642/),[μM] / [h·l],2.75,1270,DB00215,Citalopram
,19710642,area under plasma concentration-time curve extrapolated to infinity (AUC(0-infinity)),The median area under plasma concentration-time curve extrapolated to infinity (AUC(0-infinity)) of (+)-M1 was 2.75 micromol/l.h after placebo pretreatment compared with 1.95 micromol/l.h after escitalopram (P = 0.0027).,Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19710642/),[μM] / [h·l],1.95,1271,DB00215,Citalopram
,19710642,AUEC(1-12),"The mean AUEC(1-12) of CPT were 4,140 and 4,388 cm.s after placebo and escitalopram, respectively (P = 0.71).",Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19710642/),cm·s,"4,140",1272,DB00215,Citalopram
,19710642,AUEC(1-12),"The mean AUEC(1-12) of CPT were 4,140 and 4,388 cm.s after placebo and escitalopram, respectively (P = 0.71).",Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19710642/),cm·s,"4,388",1273,DB00215,Citalopram
,19101918,flow rate,"Chromatographic separation was operated with 0.2% ammonia solution:acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a Hypurity C(18) column with a total run time of 3.2 min.",Highly sensitive method for the determination of ropinirole with a lower limit of quantitation of 3.45 pg/mL in human plasma by LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19101918/),[ml] / [min],0.50,2584,DB00215,Citalopram
,19101918,total run time,"Chromatographic separation was operated with 0.2% ammonia solution:acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a Hypurity C(18) column with a total run time of 3.2 min.",Highly sensitive method for the determination of ropinirole with a lower limit of quantitation of 3.45 pg/mL in human plasma by LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19101918/),min,3.2,2585,DB00215,Citalopram
,19101918,ion transitions,The MS/MS ion transitions monitored were 261.2 --> 114.2 for RPR and 325.1 --> 209.0 for IS.,Highly sensitive method for the determination of ropinirole with a lower limit of quantitation of 3.45 pg/mL in human plasma by LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19101918/),,261.2,2586,DB00215,Citalopram
,19101918,ion transitions,The MS/MS ion transitions monitored were 261.2 --> 114.2 for RPR and 325.1 --> 209.0 for IS.,Highly sensitive method for the determination of ropinirole with a lower limit of quantitation of 3.45 pg/mL in human plasma by LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19101918/),,114.2,2587,DB00215,Citalopram
,19101918,ion transitions,The MS/MS ion transitions monitored were 261.2 --> 114.2 for RPR and 325.1 --> 209.0 for IS.,Highly sensitive method for the determination of ropinirole with a lower limit of quantitation of 3.45 pg/mL in human plasma by LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19101918/),,325.1,2588,DB00215,Citalopram
,19101918,ion transitions,The MS/MS ion transitions monitored were 261.2 --> 114.2 for RPR and 325.1 --> 209.0 for IS.,Highly sensitive method for the determination of ropinirole with a lower limit of quantitation of 3.45 pg/mL in human plasma by LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19101918/),,209.0,2589,DB00215,Citalopram
,26446141,exposure,Endoxifen exposure was ~3-fold higher during escitalopram co-administration than during paroxetine or fluoxetine co-administration (median 387 nM·h [range 159-637 nM·h] versus 99.2 nM·h [range 70.0-210 nM·h]; P = 0.012; Wilcoxon signed-rank test).,Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446141/),h·nM,387,7523,DB00215,Citalopram
,26446141,exposure,Endoxifen exposure was ~3-fold higher during escitalopram co-administration than during paroxetine or fluoxetine co-administration (median 387 nM·h [range 159-637 nM·h] versus 99.2 nM·h [range 70.0-210 nM·h]; P = 0.012; Wilcoxon signed-rank test).,Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446141/),h·nM,99.2,7524,DB00215,Citalopram
,16615673,Plasma levels,"Plasma levels of citalopram were 1400 ng/ml, 583 ng/ml, 416 ng/ml, and 296 ng/ml, at one, six, 13, and 23 h post-ingestion, respectively.",Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),[ng] / [ml],1400,9368,DB00215,Citalopram
,16615673,Plasma levels,"Plasma levels of citalopram were 1400 ng/ml, 583 ng/ml, 416 ng/ml, and 296 ng/ml, at one, six, 13, and 23 h post-ingestion, respectively.",Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),[ng] / [ml],583,9369,DB00215,Citalopram
,16615673,Plasma levels,"Plasma levels of citalopram were 1400 ng/ml, 583 ng/ml, 416 ng/ml, and 296 ng/ml, at one, six, 13, and 23 h post-ingestion, respectively.",Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),[ng] / [ml],416,9370,DB00215,Citalopram
,16615673,Plasma levels,"Plasma levels of citalopram were 1400 ng/ml, 583 ng/ml, 416 ng/ml, and 296 ng/ml, at one, six, 13, and 23 h post-ingestion, respectively.",Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),[ng] / [ml],296,9371,DB00215,Citalopram
,16615673,elimination t1/2,The first level likely represents a predistributional level with subsequent levels giving an elimination t1/2 of 17.38 h.,Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),h,17.38,9372,DB00215,Citalopram
,16615673,t1/2,The elimination of the parent drug corresponds to an approximate t1/2 of 15-20 h in this single case.,Clinical course and toxicokinetic data following isolated citalopram overdose in an infant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615673/),h,15-20,9373,DB00215,Citalopram
,19841156,Apparent clearance (CL/F),"Apparent clearance (CL/F) and volume of distribution (V/F) for escitalopram without including any covariates in the patient population were 23.5 L/h and 884 L, respectively.","Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841156/),[l] / [h],23.5,13796,DB00215,Citalopram
,19841156,volume of distribution (V/F),"Apparent clearance (CL/F) and volume of distribution (V/F) for escitalopram without including any covariates in the patient population were 23.5 L/h and 884 L, respectively.","Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19841156/),l,884,13797,DB00215,Citalopram
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,2 to 4,14164,DB00215,Citalopram
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,7 to 15,14165,DB00215,Citalopram
,10598311,half-life,"The half-life of fluoxetine and its active metabolite norfluoxetine is respectively 2 to 4 days and 7 to 15 days, more extended than other SSRIs (approximately 1 day).",[Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598311/),d,1,14166,DB00215,Citalopram
,12387707,half-life,"Escitalopram has linear pharmacokinetics, so that plasma levels increase proportionately and predictably with increased doses and its half-life of 27 - 32 h is consistent with once-daily dosing.",Escitalopram. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12387707/),h,27 - 32,17299,DB00215,Citalopram
,20503148,R/S-CIT ratio,"The R/S-CIT ratio increased from 1.99 to 2.45 with an increase in the dose (p<0.05), and the interindividual variance in the R/S-CIT ratio was up to four-fold on the same dosage.",Serum concentrations of citalopram--dose-dependent variation in R- and S-enantiomer ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20503148/),,1.99,18431,DB00215,Citalopram
,20503148,R/S-CIT ratio,"The R/S-CIT ratio increased from 1.99 to 2.45 with an increase in the dose (p<0.05), and the interindividual variance in the R/S-CIT ratio was up to four-fold on the same dosage.",Serum concentrations of citalopram--dose-dependent variation in R- and S-enantiomer ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20503148/),,2.45,18432,DB00215,Citalopram
,10365634,plasma half-lives,The following drug plasma half-lives were measured (means +/- SD): R-CIT: 66+/-11 h; S-CIT: 42+/-13 h; R-DCIT: 228+/-148 h; S-DCIT: 93+/-35 h; R-CIT-PROP: 82+/-31 h; S-CIT-PROP: 186+/-93 h.,Pharmacokinetic consequences of a citalopram treatment discontinuation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365634/),h,66,21709,DB00215,Citalopram
,10365634,plasma half-lives,The following drug plasma half-lives were measured (means +/- SD): R-CIT: 66+/-11 h; S-CIT: 42+/-13 h; R-DCIT: 228+/-148 h; S-DCIT: 93+/-35 h; R-CIT-PROP: 82+/-31 h; S-CIT-PROP: 186+/-93 h.,Pharmacokinetic consequences of a citalopram treatment discontinuation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365634/),h,42,21710,DB00215,Citalopram
,10365634,plasma half-lives,The following drug plasma half-lives were measured (means +/- SD): R-CIT: 66+/-11 h; S-CIT: 42+/-13 h; R-DCIT: 228+/-148 h; S-DCIT: 93+/-35 h; R-CIT-PROP: 82+/-31 h; S-CIT-PROP: 186+/-93 h.,Pharmacokinetic consequences of a citalopram treatment discontinuation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365634/),h,228,21711,DB00215,Citalopram
,10365634,plasma half-lives,The following drug plasma half-lives were measured (means +/- SD): R-CIT: 66+/-11 h; S-CIT: 42+/-13 h; R-DCIT: 228+/-148 h; S-DCIT: 93+/-35 h; R-CIT-PROP: 82+/-31 h; S-CIT-PROP: 186+/-93 h.,Pharmacokinetic consequences of a citalopram treatment discontinuation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365634/),h,93,21712,DB00215,Citalopram
,10365634,plasma half-lives,The following drug plasma half-lives were measured (means +/- SD): R-CIT: 66+/-11 h; S-CIT: 42+/-13 h; R-DCIT: 228+/-148 h; S-DCIT: 93+/-35 h; R-CIT-PROP: 82+/-31 h; S-CIT-PROP: 186+/-93 h.,Pharmacokinetic consequences of a citalopram treatment discontinuation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365634/),h,82,21713,DB00215,Citalopram
,10365634,plasma half-lives,The following drug plasma half-lives were measured (means +/- SD): R-CIT: 66+/-11 h; S-CIT: 42+/-13 h; R-DCIT: 228+/-148 h; S-DCIT: 93+/-35 h; R-CIT-PROP: 82+/-31 h; S-CIT-PROP: 186+/-93 h.,Pharmacokinetic consequences of a citalopram treatment discontinuation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365634/),h,186,21714,DB00215,Citalopram
,15545305,Clearance,Clearance decreased 0.23 L/h for every year of age and increased 0.14 L/h per kilogram body weight.,Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15545305/),[l] / [h],0.23,22147,DB00215,Citalopram
,15545305,Clearance,Clearance decreased 0.23 L/h for every year of age and increased 0.14 L/h per kilogram body weight.,Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15545305/),[l] / [h·kilo],0.14,22148,DB00215,Citalopram
,28673858,permeation amount,"The optimized patch prepared with ESP-BA showed zero-order skin permeation profile and a satisfied permeation amount of three days (1059±104.9μg/cm2) in vitro, which also showed a steady-state drug plasma concentration lasting 36h in vivo and the Cmax was significantly controlled compared with the control group.","Investigate the control release effect of ion-pair in the development of escitalopram transdermal patch using FT-IR spectroscopy, molecular modeling and thermal analysis. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28673858/),[μg] / [cm2],105,22500,DB00215,Citalopram
,28673858,steady-state drug plasma concentration,"The optimized patch prepared with ESP-BA showed zero-order skin permeation profile and a satisfied permeation amount of three days (1059±104.9μg/cm2) in vitro, which also showed a steady-state drug plasma concentration lasting 36h in vivo and the Cmax was significantly controlled compared with the control group.","Investigate the control release effect of ion-pair in the development of escitalopram transdermal patch using FT-IR spectroscopy, molecular modeling and thermal analysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28673858/),h,36,22501,DB00215,Citalopram
,21883384,half-life of effect-delay,"The heart rate corrected QT interval (QT(c) ) was linearly dependent on predicted escitalopram concentration [slope = 87ms/(mgl(-1) )], using a hypothetical effect-compartment (half-life of effect-delay, 1.0h).",Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883384/),h,1.0,27818,DB00215,Citalopram
,21083123,flow rate,"After liquid-liquid extraction, the compounds were separated on a Vydac(®) C18 monomeric column (250 × 4.6 mm inner diameter × 5-µm particle size) using a mobile phase composed of acetonitrile and potassium dihydrogen phosphate buffer (34:66 v/v), delivered isocratically at a flow rate of 1.0 ml min(-1).",Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21083123/),[ml] / [min],1.0,31284,DB00215,Citalopram
,21083123,maximum concentration,"After talinolol (10 mg kg(-1)) was given orally, the maximum concentration and the AUC(0-∞) were 341.8 ± 99.4 ng ml(-1) and 976.26 ± 173.37 ng h ml(-1), respectively.",Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21083123/),[ng] / [ml],341.8,31285,DB00215,Citalopram
,21083123,AUC(0-∞),"After talinolol (10 mg kg(-1)) was given orally, the maximum concentration and the AUC(0-∞) were 341.8 ± 99.4 ng ml(-1) and 976.26 ± 173.37 ng h ml(-1), respectively.",Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21083123/),[h·ng] / [ml],976.26,31286,DB00215,Citalopram
,21083123,oral bioavailability,The oral bioavailability was approximately 52.14 ± 9.26%.,Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21083123/),%,52.14,31287,DB00215,Citalopram
,21083123,analysis time,"The advantages of our method are a small sample volume (200 µl), short analysis time (13.5 min) and a simple sample extraction and clean-up compared with multiple extraction and washing steps and a longer analysis time in previously published methods.",Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21083123/),min,13.5,31288,DB00215,Citalopram
,27129716,flow rate,Separation was achieved on Waters Acquity UPLC BEH C18 column using a gradient program at a flow rate of 0.2 mL/min.,Simultaneous determination of ambroxol and salbutamol in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129716/),[ml] / [min],0.2,43131,DB00215,Citalopram
,27129716,total analytical run time,The total analytical run time was relatively short (3 min).,Simultaneous determination of ambroxol and salbutamol in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27129716/),min,3,43132,DB00215,Citalopram
,20116349,total run time,The total run time was 3.5 min.,Simultaneous determination of citalopram and its metabolite in human plasma by LC-MS/MS applied to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20116349/),min,3.5,43264,DB00215,Citalopram
,20116349,runtime,"Compared to the best existing literatures for plasma samples, the same LOQ for CIT (0.5 ng/mL) and lower LOQ for DCIT (0.25 vs 5 ng/mL) were reached, and less sample preparation steps and runtime (3.5 vs 10 min) were taken for our method.",Simultaneous determination of citalopram and its metabolite in human plasma by LC-MS/MS applied to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20116349/),min,3.5,43265,DB00215,Citalopram
,20116349,runtime,"Compared to the best existing literatures for plasma samples, the same LOQ for CIT (0.5 ng/mL) and lower LOQ for DCIT (0.25 vs 5 ng/mL) were reached, and less sample preparation steps and runtime (3.5 vs 10 min) were taken for our method.",Simultaneous determination of citalopram and its metabolite in human plasma by LC-MS/MS applied to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20116349/),min,10,43266,DB00215,Citalopram
,19033124,flow rate,"The Agilent ZORBAX SB-C18 (3.5 microm,2.1 x 150 mm) was used as the analytical column with acetonitrile-NH4AC buffer (70:30, V/V) as the mobile phase at the flow rate of 0.3 ml/min.",[Determination of plasma escitalopram with liquid chromatography-mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033124/),[ml] / [min],0.3,52426,DB00215,Citalopram
,19033124,m,"The sample was ionized by electrospray ionization source in the triple quadruple tandem mass spectrometer, and the plasma escitalopram determined with a multiple reaction monitoring mode of m/z325.4-->109.4.",[Determination of plasma escitalopram with liquid chromatography-mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033124/),,325.4,52427,DB00215,Citalopram
,19033124,m,"The sample was ionized by electrospray ionization source in the triple quadruple tandem mass spectrometer, and the plasma escitalopram determined with a multiple reaction monitoring mode of m/z325.4-->109.4.",[Determination of plasma escitalopram with liquid chromatography-mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033124/),,109.4,52428,DB00215,Citalopram
,19033124,absolute recovery,"The linear range was 0.0866-64.13 microg/L (r=0.9965) for escitalopram in human plasma, with the absolute recovery between 64.98% and 78.72% and the within-day and between-day deviations less than 10%.",[Determination of plasma escitalopram with liquid chromatography-mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033124/),%,64.98,52429,DB00215,Citalopram
,19033124,absolute recovery,"The linear range was 0.0866-64.13 microg/L (r=0.9965) for escitalopram in human plasma, with the absolute recovery between 64.98% and 78.72% and the within-day and between-day deviations less than 10%.",[Determination of plasma escitalopram with liquid chromatography-mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19033124/),%,78.72,52430,DB00215,Citalopram
,33647579,maximal QT prolongation,The average estimated maximal QT prolongation was 5.4 ms (range: 1.9-7.6 ms).,Population pharmacokinetic/pharmacodynamic modeling of delayed effect of escitalopram-induced QT prolongation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33647579/),ms,5.4,52612,DB00215,Citalopram
,33647579,equilibrium half-life,The equilibrium half-life of delayed QT prolongation was 1.9 h.,Population pharmacokinetic/pharmacodynamic modeling of delayed effect of escitalopram-induced QT prolongation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33647579/),h,1.9,52613,DB00215,Citalopram
,16433872,half-life of effect-delay,"The heart-rate corrected QT interval was linearly dependent on the predicted citalopram concentration (slope = 40 ms l mg(-1), between-subject CV = 70%) in a hypothetical effect-compartment (half-life of effect-delay = 1.4 h).",Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16433872/),h,1.4,54431,DB00215,Citalopram
less,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,24,56611,DB00215,Citalopram
,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),d,2,56612,DB00215,Citalopram
,7834966,tmax,"All 3 of the structurally unique newer antidepressants [amfebutamone (bupropion), viloxazine venlafaxine] have relatively short tmax values (1 to 2 hours), which may relate to the early onset of adverse effects.",Pharmacokinetic optimisation of therapy with newer antidepressants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,1 to 2,56613,DB00215,Citalopram
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),d,1 and 4,62758,DB00215,Citalopram
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),d,7 and 15,62759,DB00215,Citalopram
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),h,21,62760,DB00215,Citalopram
,10674711,half-lives,"Under steady-state concentrations, their half-lives range between 1 and 4 days for fluoxetine (7 and 15 days for norfluoxetine) and between 21 (paroxetine) and 36 (citalopram) hr for the other SSRIs.",Pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10674711/),h,36,62761,DB00215,Citalopram
,17442639,m/z,"The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 256.0>167.0 and m/z 325.0>109.0 for I and II, respectively.",Determination of dimenhydrinate in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a relative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442639/),,256.0,64109,DB00215,Citalopram
>,17442639,m/z,"The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 256.0>167.0 and m/z 325.0>109.0 for I and II, respectively.",Determination of dimenhydrinate in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a relative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442639/),,167.0,64110,DB00215,Citalopram
>,17442639,m/z,"The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 256.0>167.0 and m/z 325.0>109.0 for I and II, respectively.",Determination of dimenhydrinate in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a relative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442639/),,325.0,64111,DB00215,Citalopram
>,17442639,m/z,"The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 256.0>167.0 and m/z 325.0>109.0 for I and II, respectively.",Determination of dimenhydrinate in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a relative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442639/),,109.0,64112,DB00215,Citalopram
,17442639,limit of quantification (LOQ),"The limit of quantification (LOQ) was 0.4 ng/mL, the dynamic range being 0.4-200 ng/mL.",Determination of dimenhydrinate in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a relative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442639/),[ng] / [ml],0.4,64113,DB00215,Citalopram
,17014998,efficacy (I(max)),"The efficacy (I(max)) and potency (IC(50)) of inhibition of reuptake were 0.9+/-0.03 and 4.4+/-1.4 ng/ml, respectively, corresponding to an EC(50) of escitalopram about 30 ng/ml.",Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: application to escitalopram-induced effects on brain serotonin levels. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014998/),[ng] / [ml],0.9,70262,DB00215,Citalopram
,17014998,potency (IC(50)),"The efficacy (I(max)) and potency (IC(50)) of inhibition of reuptake were 0.9+/-0.03 and 4.4+/-1.4 ng/ml, respectively, corresponding to an EC(50) of escitalopram about 30 ng/ml.",Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: application to escitalopram-induced effects on brain serotonin levels. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014998/),[ng] / [ml],4.4,70263,DB00215,Citalopram
,17014998,EC(50),"The efficacy (I(max)) and potency (IC(50)) of inhibition of reuptake were 0.9+/-0.03 and 4.4+/-1.4 ng/ml, respectively, corresponding to an EC(50) of escitalopram about 30 ng/ml.",Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: application to escitalopram-induced effects on brain serotonin levels. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17014998/),[ng] / [ml],30,70264,DB00215,Citalopram
,23179471,AUC(last),"Mean (SD) AUC(last), AUC(∞) and C(max) were 1436 (341) ng · h/mL, 1595 (381) ng · h/mL and 32.3 (5.9) ng/mL, respectively, for the test formulation, and 1444 (388) ng · h/mL, 1648 (504) ng · h/mL, 33.1 (7.4) ng/mL, respectively, for the reference formulation.","Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179471/),[h·ng] / [ml],1436,75641,DB00215,Citalopram
,23179471,AUC(∞),"Mean (SD) AUC(last), AUC(∞) and C(max) were 1436 (341) ng · h/mL, 1595 (381) ng · h/mL and 32.3 (5.9) ng/mL, respectively, for the test formulation, and 1444 (388) ng · h/mL, 1648 (504) ng · h/mL, 33.1 (7.4) ng/mL, respectively, for the reference formulation.","Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179471/),[h·ng] / [ml],1595,75642,DB00215,Citalopram
,23179471,AUC(∞),"Mean (SD) AUC(last), AUC(∞) and C(max) were 1436 (341) ng · h/mL, 1595 (381) ng · h/mL and 32.3 (5.9) ng/mL, respectively, for the test formulation, and 1444 (388) ng · h/mL, 1648 (504) ng · h/mL, 33.1 (7.4) ng/mL, respectively, for the reference formulation.","Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179471/),[h·ng] / [ml],1444,75643,DB00215,Citalopram
,23179471,AUC(∞),"Mean (SD) AUC(last), AUC(∞) and C(max) were 1436 (341) ng · h/mL, 1595 (381) ng · h/mL and 32.3 (5.9) ng/mL, respectively, for the test formulation, and 1444 (388) ng · h/mL, 1648 (504) ng · h/mL, 33.1 (7.4) ng/mL, respectively, for the reference formulation.","Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179471/),[h·ng] / [ml],1648,75644,DB00215,Citalopram
,23179471,C(max),"Mean (SD) AUC(last), AUC(∞) and C(max) were 1436 (341) ng · h/mL, 1595 (381) ng · h/mL and 32.3 (5.9) ng/mL, respectively, for the test formulation, and 1444 (388) ng · h/mL, 1648 (504) ng · h/mL, 33.1 (7.4) ng/mL, respectively, for the reference formulation.","Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179471/),[ng] / [ml],32.3,75645,DB00215,Citalopram
,23179471,C(max),"Mean (SD) AUC(last), AUC(∞) and C(max) were 1436 (341) ng · h/mL, 1595 (381) ng · h/mL and 32.3 (5.9) ng/mL, respectively, for the test formulation, and 1444 (388) ng · h/mL, 1648 (504) ng · h/mL, 33.1 (7.4) ng/mL, respectively, for the reference formulation.","Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179471/),[ng] / [ml],33.1,75646,DB00215,Citalopram
,23179471,time to reach C(max) (t(max)),Median (range) time to reach C(max) (t(max)) was 2 (1-12) hours (test) and 3 (1-6) hours (reference).,"Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179471/),h,2,75647,DB00215,Citalopram
,23179471,time to reach C(max) (t(max)),Median (range) time to reach C(max) (t(max)) was 2 (1-12) hours (test) and 3 (1-6) hours (reference).,"Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179471/),h,3,75648,DB00215,Citalopram
,8924193,S(+)/R(-) ratio,Determination of the citalopram enantiomers yielded a balanced S(+)/R(-) ratio of 0.9 to 1.2.,Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8924193/),,0,76966,DB00215,Citalopram
,16291715,systemic clearance,"After intravenous infusion of escitalopram, the mean systemic clearance and volume of distribution were 31 L/h and 1,100 L, respectively.",The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291715/),[l] / [h],31,79113,DB00215,Citalopram
,16291715,volume of distribution,"After intravenous infusion of escitalopram, the mean systemic clearance and volume of distribution were 31 L/h and 1,100 L, respectively.",The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291715/),l,"1,100",79114,DB00215,Citalopram
,16291715,half-lives,"The mean half-lives were 27 and 33 hours, respectively; steady state was attained within 10 days.",The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291715/),h,27,79115,DB00215,Citalopram
,16291715,half-lives,"The mean half-lives were 27 and 33 hours, respectively; steady state was attained within 10 days.",The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291715/),h,33,79116,DB00215,Citalopram
,16291715,apparent volume of distribution,The apparent volume of distribution was around 20 L/kg.,The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16291715/),[l] / [kg],20,79117,DB00215,Citalopram
,24937809,flow rate,"An isocratic mobile phase of acetonitrile: 5mM ammonium acetate: formic acid (35:65:0.1, v/v/v) was applied at a flow rate of 0.25mL/min.",A validated LC-MS/MS method for the rapid quantification of vilazodone in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937809/),[ml] / [min],0.25,80785,DB00215,Citalopram
,24937809,m,Detection was performed using multiple reaction-monitoring (MRM) modes at m/z 442.4→155.3 for vilazodone and m/z 325.1→109.0 for escitalopram.,A validated LC-MS/MS method for the rapid quantification of vilazodone in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937809/),,442.4,80786,DB00215,Citalopram
,24937809,total analysis time,The total analysis time was 2.2min.,A validated LC-MS/MS method for the rapid quantification of vilazodone in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24937809/),min,2.2,80787,DB00215,Citalopram
,16120067,t(1/2),"Co-administration with cimetidine caused a moderate increase in the systemic exposure [AUC0, infinity] to escitalopram (geometric mean ratio = 1.72, [95% CI 1.34, 2.21]) and a small increase in t(1/2) from 23.7 to 29.0 h (5.24 h [3.75, 6.70]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,23.7,81356,DB00215,Citalopram
,16120067,t(1/2),"Co-administration with cimetidine caused a moderate increase in the systemic exposure [AUC0, infinity] to escitalopram (geometric mean ratio = 1.72, [95% CI 1.34, 2.21]) and a small increase in t(1/2) from 23.7 to 29.0 h (5.24 h [3.75, 6.70]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,29.0,81357,DB00215,Citalopram
,16120067,t(1/2),"Co-administration with cimetidine caused a moderate increase in the systemic exposure [AUC0, infinity] to escitalopram (geometric mean ratio = 1.72, [95% CI 1.34, 2.21]) and a small increase in t(1/2) from 23.7 to 29.0 h (5.24 h [3.75, 6.70]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,5.24,81358,DB00215,Citalopram
,16120067,"AUC(0, infinity)","Co-administration with omeprazole also resulted in a moderate increase in the escitalopram AUC(0, infinity) (1.51 [1.39, 1.64]) and a small increase in t(1/2) from 26.5 to 34.8 h (8.3 h [6.44, 10.2]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),,1.51,81359,DB00215,Citalopram
,16120067,t(1/2),"Co-administration with omeprazole also resulted in a moderate increase in the escitalopram AUC(0, infinity) (1.51 [1.39, 1.64]) and a small increase in t(1/2) from 26.5 to 34.8 h (8.3 h [6.44, 10.2]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,26.5,81360,DB00215,Citalopram
,16120067,t(1/2),"Co-administration with omeprazole also resulted in a moderate increase in the escitalopram AUC(0, infinity) (1.51 [1.39, 1.64]) and a small increase in t(1/2) from 26.5 to 34.8 h (8.3 h [6.44, 10.2]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,34.8,81361,DB00215,Citalopram
,16120067,t(1/2),"Co-administration with omeprazole also resulted in a moderate increase in the escitalopram AUC(0, infinity) (1.51 [1.39, 1.64]) and a small increase in t(1/2) from 26.5 to 34.8 h (8.3 h [6.44, 10.2]).",The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120067/),h,8.3,81362,DB00215,Citalopram
,19912165,half-life,The in vivo half-life predicted for timolol was 3.7 hr.,Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),h,3.7,82486,DB00215,Citalopram
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,1.4,82487,DB00215,Citalopram
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,2.0,82488,DB00215,Citalopram
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,3.5,82489,DB00215,Citalopram
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,21,82490,DB00215,Citalopram
,19912165,IC(50),"Fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine inhibited the formation of M1 in microsomes with IC(50) values of 1.4, 2.0, 3.5, 21 and 20 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,20,82491,DB00215,Citalopram
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,0.7,82492,DB00215,Citalopram
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,0.5,82493,DB00215,Citalopram
,19912165,IC(50),"In human cryo-preserved hepatocytes, the IC(50) values for fluoxetine, paroxetine and fluvoxamine were 0.7, 0.5 and 5.9 microM, respectively.",Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19912165/),μM,5.9,82494,DB00215,Citalopram
,11393715,run time,The run time was 2.6 min.,Rapid determination of citalopram in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11393715/),min,2.6,83879,DB00215,Citalopram
,11393715,limit of quant,The limit of quantitation was 0.96 ng/ml using 1 ml of plasma.,Rapid determination of citalopram in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11393715/),[ng] / [ml],0.96,83880,DB00215,Citalopram
,22460466,limits of detection (LOD),The limits of detection (LOD) and quantification (LOQ) were: 7 and 10 ng/ml respectively.,Influence of tobacco smoke on the pharmacokinetics of citalopram and its enantiomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460466/),[ng] / [ml],7,88760,DB00215,Citalopram
,22460466,limits of detection (LOD),The limits of detection (LOD) and quantification (LOQ) were: 7 and 10 ng/ml respectively.,Influence of tobacco smoke on the pharmacokinetics of citalopram and its enantiomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460466/),[ng] / [ml],10,88761,DB00215,Citalopram
,22460466,quantification (LOQ),The limits of detection (LOD) and quantification (LOQ) were: 7 and 10 ng/ml respectively.,Influence of tobacco smoke on the pharmacokinetics of citalopram and its enantiomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460466/),[ng] / [ml],10,88762,DB00215,Citalopram
,22460466,limits of detection (LOD),The limits of detection (LOD) and quantification (LOQ) were: 6 and 15 ng/ml for R- and S-CIT respectively.,Influence of tobacco smoke on the pharmacokinetics of citalopram and its enantiomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460466/),[ng] / [ml],6,88763,DB00215,Citalopram
,22460466,limits of detection (LOD),The limits of detection (LOD) and quantification (LOQ) were: 6 and 15 ng/ml for R- and S-CIT respectively.,Influence of tobacco smoke on the pharmacokinetics of citalopram and its enantiomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460466/),[ng] / [ml],15,88764,DB00215,Citalopram
,22460466,quantification (LOQ),The limits of detection (LOD) and quantification (LOQ) were: 6 and 15 ng/ml for R- and S-CIT respectively.,Influence of tobacco smoke on the pharmacokinetics of citalopram and its enantiomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460466/),[ng] / [ml],15,88765,DB00215,Citalopram
,15866490,flow-rate,"The HPLC separation of the analytes was performed on a MACHEREY-NAGEL C(18) (250 mmx4.6 mm, 5 microm, Germany) column, using water (formic acid 0.6 per thousand, ammonium acetate: 30 mmol/l)-acetonitrile (35:65, v/v) as mobile phase, with a flow-rate of 0.85 ml/min.","Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),[ml] / [min],0.85,96981,DB00215,Citalopram
above,15866490,extraction recoveries,The average extraction recoveries for all the four analytes were above 73.2%.,"Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),%,73.2,96982,DB00215,Citalopram
higher,15866490,recoveries,The methodology recoveries were higher than 95.0%.,"Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),%,95.0,96983,DB00215,Citalopram
,15866490,limits of detection (LODs),"The limits of detection (LODs) were 0.5, 0.3, 0.3 and 0.1 ng/ml for fluoxetine, citalopram, paroxetine and venlafaxine, respectively.","Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),[ng] / [ml],0.5,96984,DB00215,Citalopram
,15866490,limits of detection (LODs),"The limits of detection (LODs) were 0.5, 0.3, 0.3 and 0.1 ng/ml for fluoxetine, citalopram, paroxetine and venlafaxine, respectively.","Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),[ng] / [ml],0.3,96985,DB00215,Citalopram
,15866490,limits of detection (LODs),"The limits of detection (LODs) were 0.5, 0.3, 0.3 and 0.1 ng/ml for fluoxetine, citalopram, paroxetine and venlafaxine, respectively.","Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866490/),[ng] / [ml],0.1,96986,DB00215,Citalopram
,10774637,R/S-ratio,"For the dose of 20 mg (n = 14) mean values +/- SD of R- (and S-CIT) averaged 36.2+/-15.0 (27.4+/-13.1) ng/mL, respectively (mean R/S-ratio: 1.4+/-0.4), for R- (and S-DM-CIT) 7.2+/-3.1 (7.7+/-3.8) ng/mL, respectively (R/S-ratio: 1.0+/-0.3) whereas DDM-CIT was only detectable as R-enantiomer in 8 cases (13.2+/-12.1 ng/mL; range: 2.2-36.2 ng/mL).",Stereoselective HPLC-assay for citalopram and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774637/),,1.4,99018,DB00215,Citalopram
,10774637,R/S-ratio,"For the dose of 20 mg (n = 14) mean values +/- SD of R- (and S-CIT) averaged 36.2+/-15.0 (27.4+/-13.1) ng/mL, respectively (mean R/S-ratio: 1.4+/-0.4), for R- (and S-DM-CIT) 7.2+/-3.1 (7.7+/-3.8) ng/mL, respectively (R/S-ratio: 1.0+/-0.3) whereas DDM-CIT was only detectable as R-enantiomer in 8 cases (13.2+/-12.1 ng/mL; range: 2.2-36.2 ng/mL).",Stereoselective HPLC-assay for citalopram and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774637/),[ng] / [ml],7.2,99019,DB00215,Citalopram
,10774637,R/S-ratio,"For the dose of 20 mg (n = 14) mean values +/- SD of R- (and S-CIT) averaged 36.2+/-15.0 (27.4+/-13.1) ng/mL, respectively (mean R/S-ratio: 1.4+/-0.4), for R- (and S-DM-CIT) 7.2+/-3.1 (7.7+/-3.8) ng/mL, respectively (R/S-ratio: 1.0+/-0.3) whereas DDM-CIT was only detectable as R-enantiomer in 8 cases (13.2+/-12.1 ng/mL; range: 2.2-36.2 ng/mL).",Stereoselective HPLC-assay for citalopram and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774637/),[ng] / [ml],7.7,99020,DB00215,Citalopram
,10774637,R/S-ratio,"For the dose of 20 mg (n = 14) mean values +/- SD of R- (and S-CIT) averaged 36.2+/-15.0 (27.4+/-13.1) ng/mL, respectively (mean R/S-ratio: 1.4+/-0.4), for R- (and S-DM-CIT) 7.2+/-3.1 (7.7+/-3.8) ng/mL, respectively (R/S-ratio: 1.0+/-0.3) whereas DDM-CIT was only detectable as R-enantiomer in 8 cases (13.2+/-12.1 ng/mL; range: 2.2-36.2 ng/mL).",Stereoselective HPLC-assay for citalopram and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774637/),,1.0,99021,DB00215,Citalopram
,10774637,R/S-ratio,"For the dose of 20 mg (n = 14) mean values +/- SD of R- (and S-CIT) averaged 36.2+/-15.0 (27.4+/-13.1) ng/mL, respectively (mean R/S-ratio: 1.4+/-0.4), for R- (and S-DM-CIT) 7.2+/-3.1 (7.7+/-3.8) ng/mL, respectively (R/S-ratio: 1.0+/-0.3) whereas DDM-CIT was only detectable as R-enantiomer in 8 cases (13.2+/-12.1 ng/mL; range: 2.2-36.2 ng/mL).",Stereoselective HPLC-assay for citalopram and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10774637/),[ng] / [ml],13.2,99022,DB00215,Citalopram
,9681666,absolute bioavailability,The absolute bioavailability of citalopram tablets in healthy subjects was 80%.,Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9681666/),%,80,109152,DB00215,Citalopram
,9681666,t1/2,"In comparison with healthy subjects, renal impairment was associated with a significant reduction in the renal elimination of citalopram and its two metabolites and a slight prolongation of serum citalopram t1/2 (49.5 h vs 36.8 h in healthy subjects).",Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9681666/),h,49.5,109153,DB00215,Citalopram
,9681666,t1/2,"In comparison with healthy subjects, renal impairment was associated with a significant reduction in the renal elimination of citalopram and its two metabolites and a slight prolongation of serum citalopram t1/2 (49.5 h vs 36.8 h in healthy subjects).",Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9681666/),h,36.8,109154,DB00215,Citalopram
,9681666,CLoral,Cirrhosis resulted in significant decrease in citalopram CLoral (0.21 vs 0.331 x h(-1) x kg(-1) in healthy subjects) and increase in Vz x f(-1) with an approximately twofold increase in t1/2 (83.4 h vs 36.8 h in healthy subjects).,Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9681666/),1/[h·kg],0.21,109155,DB00215,Citalopram
,9681666,CLoral,Cirrhosis resulted in significant decrease in citalopram CLoral (0.21 vs 0.331 x h(-1) x kg(-1) in healthy subjects) and increase in Vz x f(-1) with an approximately twofold increase in t1/2 (83.4 h vs 36.8 h in healthy subjects).,Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9681666/),1/[h·kg],0.331,109156,DB00215,Citalopram
,9681666,t1/2,Cirrhosis resulted in significant decrease in citalopram CLoral (0.21 vs 0.331 x h(-1) x kg(-1) in healthy subjects) and increase in Vz x f(-1) with an approximately twofold increase in t1/2 (83.4 h vs 36.8 h in healthy subjects).,Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9681666/),h,83.4,109157,DB00215,Citalopram
,9681666,t1/2,Cirrhosis resulted in significant decrease in citalopram CLoral (0.21 vs 0.331 x h(-1) x kg(-1) in healthy subjects) and increase in Vz x f(-1) with an approximately twofold increase in t1/2 (83.4 h vs 36.8 h in healthy subjects).,Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9681666/),h,36.8,109158,DB00215,Citalopram
,3929295,steady state citalopram levels,The recorded steady state citalopram levels of 140-545 nM after a once-daily 20-mg dose were up to four times higher than expected from data in younger patients and volunteers.,Kinetics of citalopram in elderly patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3929295/),nM,140-545,109437,DB00215,Citalopram
,3929295,biological half-life,"The biological half-life (1.5-3.75 days) and estimated systemic clearance (0.08-0.3 1/min) also differed from data in younger individuals (1.5 days and 0.4 1/min, respectively).",Kinetics of citalopram in elderly patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3929295/),d,1.5-3.75,109438,DB00215,Citalopram
,3929295,systemic clearance,"The biological half-life (1.5-3.75 days) and estimated systemic clearance (0.08-0.3 1/min) also differed from data in younger individuals (1.5 days and 0.4 1/min, respectively).",Kinetics of citalopram in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3929295/),[1] / [min],0.08-0.3,109439,DB00215,Citalopram
,3929295,systemic clearance,"The biological half-life (1.5-3.75 days) and estimated systemic clearance (0.08-0.3 1/min) also differed from data in younger individuals (1.5 days and 0.4 1/min, respectively).",Kinetics of citalopram in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3929295/),d,1.5,109440,DB00215,Citalopram
,3929295,systemic clearance,"The biological half-life (1.5-3.75 days) and estimated systemic clearance (0.08-0.3 1/min) also differed from data in younger individuals (1.5 days and 0.4 1/min, respectively).",Kinetics of citalopram in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3929295/),[1] / [min],0.4,109441,DB00215,Citalopram
,22677485,flow rate,The mobile phase is acetonitrile-phosphate buffer (pH 3.6) 28:72% v/v at a flow rate of 1.0 mL/min.,High-performance liquid chromatographic assay for ziprasidone in plasma samples: application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677485/),[ml] / [min],1.0,110028,DB00215,Citalopram
,22677485,recoveries,"The mean recoveries of ZRS and IS are 79.32 ± 1.16 and 84.10 ± 3.2%, respectively.",High-performance liquid chromatographic assay for ziprasidone in plasma samples: application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677485/),%,79.32,110029,DB00215,Citalopram
,22677485,recoveries,"The mean recoveries of ZRS and IS are 79.32 ± 1.16 and 84.10 ± 3.2%, respectively.",High-performance liquid chromatographic assay for ziprasidone in plasma samples: application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677485/),%,84.10,110030,DB00215,Citalopram
,16430026,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax), of 34.77 ng/ml (test) and 34.42 ng/ml (reference) were achieved.","Bioavailability investigation of two different oral formulations of citalopram, a so-called 'second generation' antidepressant drug. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430026/),[ng] / [ml],34.77,115722,DB00215,Citalopram
,16430026,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax), of 34.77 ng/ml (test) and 34.42 ng/ml (reference) were achieved.","Bioavailability investigation of two different oral formulations of citalopram, a so-called 'second generation' antidepressant drug. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430026/),[ng] / [ml],34.42,115723,DB00215,Citalopram
,16430026,Areas under the plasma concentration-time curve (AUC0-infinity),"Areas under the plasma concentration-time curve (AUC0-infinity) of 1,719.69 ng*h/ml (test) and 1,725.71 ng*h/ml (reference) were determined.","Bioavailability investigation of two different oral formulations of citalopram, a so-called 'second generation' antidepressant drug. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430026/),[h·ng] / [ml],"1,719.69",115724,DB00215,Citalopram
,16430026,Areas under the plasma concentration-time curve (AUC0-infinity),"Areas under the plasma concentration-time curve (AUC0-infinity) of 1,719.69 ng*h/ml (test) and 1,725.71 ng*h/ml (reference) were determined.","Bioavailability investigation of two different oral formulations of citalopram, a so-called 'second generation' antidepressant drug. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430026/),[h·ng] / [ml],"1,725.71",115725,DB00215,Citalopram
,16430026,tmax,"Thus, tmax showed values of 3.29 h (test) and 3.77 h (reference).","Bioavailability investigation of two different oral formulations of citalopram, a so-called 'second generation' antidepressant drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430026/),h,3.29,115726,DB00215,Citalopram
,16430026,tmax,"Thus, tmax showed values of 3.29 h (test) and 3.77 h (reference).","Bioavailability investigation of two different oral formulations of citalopram, a so-called 'second generation' antidepressant drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430026/),h,3.77,115727,DB00215,Citalopram
,16430026,plasma elimination half-life (t1/2),The plasma elimination half-life (t1/2) was 42.50 h (test) und 44.46 h (reference).,"Bioavailability investigation of two different oral formulations of citalopram, a so-called 'second generation' antidepressant drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430026/),h,42.50,115728,DB00215,Citalopram
,16430026,plasma elimination half-life (t1/2),The plasma elimination half-life (t1/2) was 42.50 h (test) und 44.46 h (reference).,"Bioavailability investigation of two different oral formulations of citalopram, a so-called 'second generation' antidepressant drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430026/),h,44.46,115729,DB00215,Citalopram
,11343579,S-Cit/R-Cit ratio,"Plasma concentrations of S-Cit and R-Cit significantly increased from day 0 (means+/-S.D.: 28+/-9 and 47+/-11 &mgr;g/l, respectively) to day 49 (58+/-12 and 72+/-21 &mgr;g/l, respectively) (p & 0.01 for each comparison), and the S-Cit/R-Cit ratio increased from 0.61+/-0.16 to 0.82+/-0.12 (p & 0.01).",Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11343579/),,0.61,116091,DB00215,Citalopram
,11343579,S-Cit/R-Cit ratio,"Plasma concentrations of S-Cit and R-Cit significantly increased from day 0 (means+/-S.D.: 28+/-9 and 47+/-11 &mgr;g/l, respectively) to day 49 (58+/-12 and 72+/-21 &mgr;g/l, respectively) (p & 0.01 for each comparison), and the S-Cit/R-Cit ratio increased from 0.61+/-0.16 to 0.82+/-0.12 (p & 0.01).",Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11343579/),,0.82,116092,DB00215,Citalopram
,22354844,flow rate,"Chromatographic separation was achieved using an isocratic mobile phase (0.2% formic acid-acetonitrile, 20:80, v/v) at a flow rate of 0.6 mL/min on an Atlantis dC₁₈ column (maintained at 40 ± 1 °C) with a total run time of 2.0 min.",Development and validation of a highly sensitive LC-MS/MS-ESI method for the determination of nobiletin in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22354844/),[ml] / [min],0.6,122656,DB00215,Citalopram
,22354844,total run time,"Chromatographic separation was achieved using an isocratic mobile phase (0.2% formic acid-acetonitrile, 20:80, v/v) at a flow rate of 0.6 mL/min on an Atlantis dC₁₈ column (maintained at 40 ± 1 °C) with a total run time of 2.0 min.",Development and validation of a highly sensitive LC-MS/MS-ESI method for the determination of nobiletin in rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22354844/),min,2.0,122657,DB00215,Citalopram
higher,17722014,Recovery,Recovery was higher than 70% for both enantiomers.,Enantioselective analysis of citalopram and demethylcitalopram in human and rat plasma by chiral LC-MS/MS: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17722014/),%,70,127841,DB00215,Citalopram
,17722014,S/R AUC ratios,"The results showed a higher proportion of the (-)-(R)-CITA in human and rat plasma, with S/R AUC ratios for CITA of 0.28 and 0.44, respectively.",Enantioselective analysis of citalopram and demethylcitalopram in human and rat plasma by chiral LC-MS/MS: application to pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17722014/),,0.28,127842,DB00215,Citalopram
,17722014,S/R AUC ratios,"The results showed a higher proportion of the (-)-(R)-CITA in human and rat plasma, with S/R AUC ratios for CITA of 0.28 and 0.44, respectively.",Enantioselective analysis of citalopram and demethylcitalopram in human and rat plasma by chiral LC-MS/MS: application to pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17722014/),,0.44,127843,DB00215,Citalopram
,17722014,S/R AUC ratios,S/R AUC ratios of DCITA were 0.48 for rats and 1.04 for the healthy volunteer.,Enantioselective analysis of citalopram and demethylcitalopram in human and rat plasma by chiral LC-MS/MS: application to pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17722014/),,0.48,127844,DB00215,Citalopram
,17722014,S/R AUC ratios,S/R AUC ratios of DCITA were 0.48 for rats and 1.04 for the healthy volunteer.,Enantioselective analysis of citalopram and demethylcitalopram in human and rat plasma by chiral LC-MS/MS: application to pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17722014/),,1.04,127845,DB00215,Citalopram
,9068931,half-life (t1/2),Most SSRIs have a half-life (t1/2) of approximately 1 day.,Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068931/),d,1,129521,DB00215,Citalopram
,9068931,t1/2,"Fluoxetine, however, has a longer t1/2 of 2 to 4 days, and its active metabolite, norfluoxetine, has an extended t1/2 of 7 to 15 days.",Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068931/),d,2 to 4,129522,DB00215,Citalopram
,9068931,t1/2,"Fluoxetine, however, has a longer t1/2 of 2 to 4 days, and its active metabolite, norfluoxetine, has an extended t1/2 of 7 to 15 days.",Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068931/),d,7 to 15,129523,DB00215,Citalopram
,9679303,Recoveries,"Recoveries measured at three concentrations range from 81 to 118% for the tertiary amines (citalopram and the internal standard methylmaprotiline), 73 to 95% for the secondary amines (desmethylcitalopram, paroxetine and sertraline), and 39 to 66% for the primary amines (didesmethylcitalopram and desmethylsertraline).","Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9679303/),%,81 to 118,129741,DB00215,Citalopram
,9679303,Recoveries,"Recoveries measured at three concentrations range from 81 to 118% for the tertiary amines (citalopram and the internal standard methylmaprotiline), 73 to 95% for the secondary amines (desmethylcitalopram, paroxetine and sertraline), and 39 to 66% for the primary amines (didesmethylcitalopram and desmethylsertraline).","Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9679303/),%,73 to 95,129742,DB00215,Citalopram
,9679303,Recoveries,"Recoveries measured at three concentrations range from 81 to 118% for the tertiary amines (citalopram and the internal standard methylmaprotiline), 73 to 95% for the secondary amines (desmethylcitalopram, paroxetine and sertraline), and 39 to 66% for the primary amines (didesmethylcitalopram and desmethylsertraline).","Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9679303/),%,39 to 66,129743,DB00215,Citalopram
,20848647,concentrations ratios,"The enantiomeric (S/R) concentrations ratios of citalopram were lower in the DA rats when compared with the SD rats (0.53 ± 0.05 vs. 0.80 ± 0.03, P < 0.001), indicating a possibly decreased capacity in the metabolism of the (-)-(R)-enantiomer in the DA rats.",Cytochrome P450-dependent disposition of the enantiomers of citalopram and its metabolites: in vivo studies in Sprague-Dawley and Dark Agouti rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848647/),,0.53,132126,DB00215,Citalopram
,20848647,concentrations ratios,"The enantiomeric (S/R) concentrations ratios of citalopram were lower in the DA rats when compared with the SD rats (0.53 ± 0.05 vs. 0.80 ± 0.03, P < 0.001), indicating a possibly decreased capacity in the metabolism of the (-)-(R)-enantiomer in the DA rats.",Cytochrome P450-dependent disposition of the enantiomers of citalopram and its metabolites: in vivo studies in Sprague-Dawley and Dark Agouti rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20848647/),,0.80,132127,DB00215,Citalopram
>,10599932,metabolic ratio,"The CYP2D6 phenotype, determined when the patient received the antidepressant comedication, characterized a poor metabolizer status (dextromethorphan metabolic ratio >0.3), despite a heterozygous genotype containing a wild-type allele with extensive metabolic capacity and a mutant non-functional allele (CYP2D6*1A/CYP2D6*4A).",Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599932/),,0.3,133345,DB00215,Citalopram
,10546982,production rate constant,"In the hippocampus, the production rate constant was 2.36 fmol mg protein (-1)h(-1); the degradation rate constant was 0.0077 h(-1); and the half-life of the SERT recovery was 3.4 days.",Serotonin transporter production and degradation rates: studies with RTI-76. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546982/),[fmol·mg] / [(-1)h],2.36,134522,DB00215,Citalopram
,10546982,degradation rate constant,"In the hippocampus, the production rate constant was 2.36 fmol mg protein (-1)h(-1); the degradation rate constant was 0.0077 h(-1); and the half-life of the SERT recovery was 3.4 days.",Serotonin transporter production and degradation rates: studies with RTI-76. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546982/),1/[h],0.0077,134523,DB00215,Citalopram
,10546982,half-life of,"In the hippocampus, the production rate constant was 2.36 fmol mg protein (-1)h(-1); the degradation rate constant was 0.0077 h(-1); and the half-life of the SERT recovery was 3.4 days.",Serotonin transporter production and degradation rates: studies with RTI-76. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10546982/),d,3.4,134524,DB00215,Citalopram
,17633218,flow-rate,"The mobile phase consisted of acetonitrile-water-formic acid (60:40:0.2), at a flow-rate of 0.5 mL x min(-1).",[Determination of citalopram in human plasma with LC-MS/MS method and its bioequivalent evaluation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17633218/),[ml] / [min],0.5,134957,DB00215,Citalopram
,17633218,bioavailability,"Calculated with AUC(0-120 h), the bioavailability of two formulations was (102.1 +/- 10.9)%.",[Determination of citalopram in human plasma with LC-MS/MS method and its bioequivalent evaluation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17633218/),%,102.1,134958,DB00215,Citalopram
,31144347,clearance,"The average escitalopram clearance and volume of distribution were 23.1 L/h (interindividual variability 51%), and 920 L, respectively.",Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31144347/),[l] / [h],23.1,136128,DB00215,Citalopram
,31144347,volume of distribution,"The average escitalopram clearance and volume of distribution were 23.1 L/h (interindividual variability 51%), and 920 L, respectively.",Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31144347/),l,920,136129,DB00215,Citalopram
,17654695,influx clearance into the brain,"The modelling resulted in an estimated influx clearance into the brain of 535 microl/min/g brain, resulting in an unbound brain-to-plasma AUC ratio of 0.8 independent of escitalopram dose.",Pharmacokinetic modelling of blood-brain barrier transport of escitalopram in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654695/),[μl] / [brain·g·min],535,140364,DB00215,Citalopram
,17654695,unbound brain-to-plasma AUC ratio,"The modelling resulted in an estimated influx clearance into the brain of 535 microl/min/g brain, resulting in an unbound brain-to-plasma AUC ratio of 0.8 independent of escitalopram dose.",Pharmacokinetic modelling of blood-brain barrier transport of escitalopram in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17654695/),,0.8,140365,DB00215,Citalopram
,17375980,elimination half-life,The elimination half-life of escitalopram is about 27-33 hours and is consistent with once-daily administration.,The clinical pharmacokinetics of escitalopram. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17375980/),h,27-33,147053,DB00215,Citalopram
,17375980,protein binding,Escitalopram has low protein binding (56%) and is not likely to cause interactions with highly protein-bound drugs.,The clinical pharmacokinetics of escitalopram. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17375980/),%,56,147054,DB00215,Citalopram
,17375980,apparent volume of distribution during the terminal phase after oral administration (V(z)/F),"It is widely distributed throughout tissues, with an apparent volume of distribution during the terminal phase after oral administration (V(z)/F) of about 1100L.",The clinical pharmacokinetics of escitalopram. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17375980/),l,1100,147055,DB00215,Citalopram
,16855453,metabolic ratios,"The metabolic ratios (plasma concentration of desmethylcitalopram to citalopram) were found to be 0.20 +/- 0.07, 0.15 +/- 0.05, and 0.07 +/- 0.03 in the homozygous EMs, heterozygous EMs, and PMs, respectively (P < 0.001, 1-way analysis of variance).",Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855453/),,0.20,147717,DB00215,Citalopram
,16855453,metabolic ratios,"The metabolic ratios (plasma concentration of desmethylcitalopram to citalopram) were found to be 0.20 +/- 0.07, 0.15 +/- 0.05, and 0.07 +/- 0.03 in the homozygous EMs, heterozygous EMs, and PMs, respectively (P < 0.001, 1-way analysis of variance).",Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855453/),,0.15,147718,DB00215,Citalopram
,16855453,metabolic ratios,"The metabolic ratios (plasma concentration of desmethylcitalopram to citalopram) were found to be 0.20 +/- 0.07, 0.15 +/- 0.05, and 0.07 +/- 0.03 in the homozygous EMs, heterozygous EMs, and PMs, respectively (P < 0.001, 1-way analysis of variance).",Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16855453/),,0.07,147719,DB00215,Citalopram
,15118482,CSF,"CSF concentrations of S-CIT and R-CIT were 10.6 +/- 4.3 and 20.9 +/- 6 ng/mL, respectively, and their CSF/plasma ratios were 52% +/- 9% and 48% +/- 6%, respectively.",Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15118482/),[ng] / [ml],10.6,149941,DB00215,Citalopram
,15118482,CSF,"CSF concentrations of S-CIT and R-CIT were 10.6 +/- 4.3 and 20.9 +/- 6 ng/mL, respectively, and their CSF/plasma ratios were 52% +/- 9% and 48% +/- 6%, respectively.",Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15118482/),[ng] / [ml],20.9,149942,DB00215,Citalopram
,15118482,concentrations,"CSF concentrations of S-CIT and R-CIT were 10.6 +/- 4.3 and 20.9 +/- 6 ng/mL, respectively, and their CSF/plasma ratios were 52% +/- 9% and 48% +/- 6%, respectively.",Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15118482/),[ng] / [ml],10.6,149943,DB00215,Citalopram
,15118482,concentrations,"CSF concentrations of S-CIT and R-CIT were 10.6 +/- 4.3 and 20.9 +/- 6 ng/mL, respectively, and their CSF/plasma ratios were 52% +/- 9% and 48% +/- 6%, respectively.",Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15118482/),[ng] / [ml],20.9,149944,DB00215,Citalopram
,15118482,CSF/plasma ratios,"CSF concentrations of S-CIT and R-CIT were 10.6 +/- 4.3 and 20.9 +/- 6 ng/mL, respectively, and their CSF/plasma ratios were 52% +/- 9% and 48% +/- 6%, respectively.",Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15118482/),%,52,149945,DB00215,Citalopram
,15118482,CSF/plasma ratios,"CSF concentrations of S-CIT and R-CIT were 10.6 +/- 4.3 and 20.9 +/- 6 ng/mL, respectively, and their CSF/plasma ratios were 52% +/- 9% and 48% +/- 6%, respectively.",Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15118482/),%,48,149946,DB00215,Citalopram
,19537522,Maximum plasma concentrations (C(max)),Maximum plasma concentrations (C(max)) of 9.85 +/- 1.79 ng/ml (test) and 9.92 +/- 2.14 ng/ml (reference) were achieved.,Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),[ng] / [ml],9.85,157337,DB00215,Citalopram
,19537522,Maximum plasma concentrations (C(max)),Maximum plasma concentrations (C(max)) of 9.85 +/- 1.79 ng/ml (test) and 9.92 +/- 2.14 ng/ml (reference) were achieved.,Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),[ng] / [ml],9.92,157338,DB00215,Citalopram
,19537522,Areas under the plasma concentration-time curve (AUC(0-infinity)),"Areas under the plasma concentration-time curve (AUC(0-infinity)) of 428.40 +/- 140.25 ng x h/ml (test) and 413.73 +/- 144.81 ng x h/ml (reference), AUC(0-t) of 401.33 +/- 120.61 ng x h/ml (test), 385.42 +/- 117.73 ng x h/ml (reference) were calculated.",Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),[h·ng] / [ml],428.40,157339,DB00215,Citalopram
,19537522,Areas under the plasma concentration-time curve (AUC(0-infinity)),"Areas under the plasma concentration-time curve (AUC(0-infinity)) of 428.40 +/- 140.25 ng x h/ml (test) and 413.73 +/- 144.81 ng x h/ml (reference), AUC(0-t) of 401.33 +/- 120.61 ng x h/ml (test), 385.42 +/- 117.73 ng x h/ml (reference) were calculated.",Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),[h·ng] / [ml],413.73,157340,DB00215,Citalopram
,19537522,AUC(0-t),"Areas under the plasma concentration-time curve (AUC(0-infinity)) of 428.40 +/- 140.25 ng x h/ml (test) and 413.73 +/- 144.81 ng x h/ml (reference), AUC(0-t) of 401.33 +/- 120.61 ng x h/ml (test), 385.42 +/- 117.73 ng x h/ml (reference) were calculated.",Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),[h·ng] / [ml],401.33,157341,DB00215,Citalopram
,19537522,AUC(0-t),"Areas under the plasma concentration-time curve (AUC(0-infinity)) of 428.40 +/- 140.25 ng x h/ml (test) and 413.73 +/- 144.81 ng x h/ml (reference), AUC(0-t) of 401.33 +/- 120.61 ng x h/ml (test), 385.42 +/- 117.73 ng x h/ml (reference) were calculated.",Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),[h·ng] / [ml],385.42,157342,DB00215,Citalopram
,19537522,T(max),"The median T(max) was 4.3 +/- 1.8h, 4.1 +/- 1.5 h for test and reference formulation, respectively.",Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),h,4.3,157343,DB00215,Citalopram
,19537522,T(max),"The median T(max) was 4.3 +/- 1.8h, 4.1 +/- 1.5 h for test and reference formulation, respectively.",Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),h,4.1,157344,DB00215,Citalopram
,19537522,Plasma elimination half-lives (t 1/2),"Plasma elimination half-lives (t 1/2) of 36.30 +/- 8.93 h (test), 36.70 +/- 9.99 h (reference) were determined.",Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),h,36.30,157345,DB00215,Citalopram
,19537522,Plasma elimination half-lives (t 1/2),"Plasma elimination half-lives (t 1/2) of 36.30 +/- 8.93 h (test), 36.70 +/- 9.99 h (reference) were determined.",Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537522/),h,36.70,157346,DB00215,Citalopram
,16119514,run time,The method had a chromatographic run time of three minutes and a linear calibration curve over the range of 0.5 - 200 ng x ml(-1) (r2 > 0.999887).,A bioequivalence study of citalopram based on quantification by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16119514/),min,three,161028,DB00215,Citalopram
,18520609,length of hospital stay,"Median length of hospital stay was 3 days (range, 1-8 days).",Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520609/),d,3,166722,DB00215,Citalopram
,1711447,elimination half-life,Its elimination half-life of 33 hours permits once daily oral administration.,"Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711447/),h,33,167736,DB00215,Citalopram
,32957789,flow rate,"The analytes of interest and internal standard (duloxetine (DUL)) were extracted from 100 μL of plasma with solid-phase extraction on an Oasis HLB cartridge followed by the separation with gradient elution with water containing 0.1% formic acid and acetonitrile on an Agilent Eclipse Plus ODS (4.6 × 100 mm, 3.5 μm) column at flow rate 0.2 mL min-1.","Toxicity Profile, Pharmacokinetic, and Drug-Drug Interaction Study of Citalopram and Sertraline Following Oral Delivery in Rat: An LC-MS/MS Method for the Simultaneous Determination in Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32957789/),[ml] / [min],0.2,168143,DB00215,Citalopram
,19179296,oral clearance (CL/F),Estimated oral clearance (CL/F) to escitalopram was statistically insensitive to reported dosing methods (MEMS vs patient reported: 25.5 [7.0%] vs 26.9 [6.6%] L/h).,The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179296/),[l] / [h],25.5,169083,DB00215,Citalopram
,19179296,oral clearance (CL/F),Estimated oral clearance (CL/F) to escitalopram was statistically insensitive to reported dosing methods (MEMS vs patient reported: 25.5 [7.0%] vs 26.9 [6.6%] L/h).,The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179296/),[l] / [h],26.9,169084,DB00215,Citalopram
,19179296,volume of distribution (V/F,"However, different dosing report methods resulted in significantly different estimates on the volume of distribution (V/F; MEMS vs patient reported: 1000 [17.3%] vs 767 [17.5%] L) and the absorption rate constant K(a) (MEMS vs patient reported: 0.74 [45.7%] vs 0.51 [35.4%] h(-1)) for escitalopram.",The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179296/),l,1000,169085,DB00215,Citalopram
,19179296,volume of distribution (V/F,"However, different dosing report methods resulted in significantly different estimates on the volume of distribution (V/F; MEMS vs patient reported: 1000 [17.3%] vs 767 [17.5%] L) and the absorption rate constant K(a) (MEMS vs patient reported: 0.74 [45.7%] vs 0.51 [35.4%] h(-1)) for escitalopram.",The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179296/),l,767,169086,DB00215,Citalopram
,19179296,absorption rate constant K(a),"However, different dosing report methods resulted in significantly different estimates on the volume of distribution (V/F; MEMS vs patient reported: 1000 [17.3%] vs 767 [17.5%] L) and the absorption rate constant K(a) (MEMS vs patient reported: 0.74 [45.7%] vs 0.51 [35.4%] h(-1)) for escitalopram.",The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179296/),1/[h],0.74,169087,DB00215,Citalopram
,19179296,absorption rate constant K(a),"However, different dosing report methods resulted in significantly different estimates on the volume of distribution (V/F; MEMS vs patient reported: 1000 [17.3%] vs 767 [17.5%] L) and the absorption rate constant K(a) (MEMS vs patient reported: 0.74 [45.7%] vs 0.51 [35.4%] h(-1)) for escitalopram.",The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179296/),1/[h],0.51,169088,DB00215,Citalopram
,19179296,V/F,"Furthermore, the parameters estimated from the MEMS method were similar to literature reported values for V/F ( approximately 1100 L) and K(a) ( approximately 0.8-0.9 h(-1)) arising from traditional pharmacokinetic approaches.",The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179296/),l,1100,169089,DB00215,Citalopram
,19179296,K(a),"Furthermore, the parameters estimated from the MEMS method were similar to literature reported values for V/F ( approximately 1100 L) and K(a) ( approximately 0.8-0.9 h(-1)) arising from traditional pharmacokinetic approaches.",The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179296/),1/[h],0.8-0.9,169090,DB00215,Citalopram
,22120786,m/z,The ion-pairs including m/z 276.2-216.2 for cyclobenzaprine and m/z 325.2-109.1 for IS were used for monitoring.,Determination of cyclobenzaprine in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22120786/),,276.2-216.2,169106,DB00215,Citalopram
,22120786,m/z,The ion-pairs including m/z 276.2-216.2 for cyclobenzaprine and m/z 325.2-109.1 for IS were used for monitoring.,Determination of cyclobenzaprine in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22120786/),,325.2-109.1,169107,DB00215,Citalopram
,27209054,total run time,The total run time was 1.5 min.,UPLC-MS-MS Method for the Determination of Vilazodone in Human Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27209054/),min,1.5,181804,DB00215,Citalopram
> or =,9629950,Response rates (delta Hamilton,"Response rates (delta Hamilton > or = 50%) amounted to 33.3% and 17.9% on Day 10, and 66.2% and 63.3% on Day 42, without a relevant group difference in citalopram plasma concentration.",A double-blind double-dummy study of citalopram comparing infusion versus oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629950/),%,50,182946,DB00215,Citalopram
,9629950,Response rates (delta Hamilton,"Response rates (delta Hamilton > or = 50%) amounted to 33.3% and 17.9% on Day 10, and 66.2% and 63.3% on Day 42, without a relevant group difference in citalopram plasma concentration.",A double-blind double-dummy study of citalopram comparing infusion versus oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629950/),%,33.3,182947,DB00215,Citalopram
,9629950,Response rates (delta Hamilton,"Response rates (delta Hamilton > or = 50%) amounted to 33.3% and 17.9% on Day 10, and 66.2% and 63.3% on Day 42, without a relevant group difference in citalopram plasma concentration.",A double-blind double-dummy study of citalopram comparing infusion versus oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629950/),%,17.9,182948,DB00215,Citalopram
,9629950,Response rates (delta Hamilton,"Response rates (delta Hamilton > or = 50%) amounted to 33.3% and 17.9% on Day 10, and 66.2% and 63.3% on Day 42, without a relevant group difference in citalopram plasma concentration.",A double-blind double-dummy study of citalopram comparing infusion versus oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629950/),%,66.2,182949,DB00215,Citalopram
,9629950,Response rates (delta Hamilton,"Response rates (delta Hamilton > or = 50%) amounted to 33.3% and 17.9% on Day 10, and 66.2% and 63.3% on Day 42, without a relevant group difference in citalopram plasma concentration.",A double-blind double-dummy study of citalopram comparing infusion versus oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629950/),%,63.3,182950,DB00215,Citalopram
,9331518,relative bioavailability,The relative bioavailability of selegiline was slightly reduced (by 29%; p = 0.008) when citalopram was coadministered compared with selegiline alone.,Lack of adverse interactions between concomitantly administered selegiline and citalopram. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331518/),,29,188189,DB00215,Citalopram
,18291131,enrichment factor,An enrichment factor of 150 along with a good sample clean-up was obtained.,Modified solvent microextraction with back extraction combined with liquid chromatography-fluorescence detection for the determination of citalopram in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18291131/),,150,188439,DB00215,Citalopram
,18291131,signal to noise ratio (S/N),"Limits of detection and quantification, based on a signal to noise ratio (S/N) of 3 and 10, were 0.3 and 0.8 ng mL(-1), respectively.",Modified solvent microextraction with back extraction combined with liquid chromatography-fluorescence detection for the determination of citalopram in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18291131/),[ng] / [ml],3,188440,DB00215,Citalopram
,18291131,signal to noise ratio (S/N),"Limits of detection and quantification, based on a signal to noise ratio (S/N) of 3 and 10, were 0.3 and 0.8 ng mL(-1), respectively.",Modified solvent microextraction with back extraction combined with liquid chromatography-fluorescence detection for the determination of citalopram in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18291131/),[ng] / [ml],10,188441,DB00215,Citalopram
,18291131,signal to noise ratio (S/N),"Limits of detection and quantification, based on a signal to noise ratio (S/N) of 3 and 10, were 0.3 and 0.8 ng mL(-1), respectively.",Modified solvent microextraction with back extraction combined with liquid chromatography-fluorescence detection for the determination of citalopram in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18291131/),[ng] / [ml],0.3,188442,DB00215,Citalopram
,18291131,signal to noise ratio (S/N),"Limits of detection and quantification, based on a signal to noise ratio (S/N) of 3 and 10, were 0.3 and 0.8 ng mL(-1), respectively.",Modified solvent microextraction with back extraction combined with liquid chromatography-fluorescence detection for the determination of citalopram in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18291131/),[ng] / [ml],0.8,188443,DB00215,Citalopram
,8451774,total clearance,"Both citalopram total clearance and demethylation clearance (formation of desmethylcitalopram) were significantly lower in poor metabolizers of mephenytoin compared to extensive metabolizers (median 15.2 vs. 27.3 and 2.6 vs. 5.9 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],15.2,193421,DB00215,Citalopram
,8451774,total clearance,"Both citalopram total clearance and demethylation clearance (formation of desmethylcitalopram) were significantly lower in poor metabolizers of mephenytoin compared to extensive metabolizers (median 15.2 vs. 27.3 and 2.6 vs. 5.9 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],27.3,193422,DB00215,Citalopram
,8451774,total clearance,"Both citalopram total clearance and demethylation clearance (formation of desmethylcitalopram) were significantly lower in poor metabolizers of mephenytoin compared to extensive metabolizers (median 15.2 vs. 27.3 and 2.6 vs. 5.9 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],2.6,193423,DB00215,Citalopram
,8451774,dem,"Both citalopram total clearance and demethylation clearance (formation of desmethylcitalopram) were significantly lower in poor metabolizers of mephenytoin compared to extensive metabolizers (median 15.2 vs. 27.3 and 2.6 vs. 5.9 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],15.2,193424,DB00215,Citalopram
,8451774,dem,"Both citalopram total clearance and demethylation clearance (formation of desmethylcitalopram) were significantly lower in poor metabolizers of mephenytoin compared to extensive metabolizers (median 15.2 vs. 27.3 and 2.6 vs. 5.9 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],27.3,193425,DB00215,Citalopram
,8451774,dem,"Both citalopram total clearance and demethylation clearance (formation of desmethylcitalopram) were significantly lower in poor metabolizers of mephenytoin compared to extensive metabolizers (median 15.2 vs. 27.3 and 2.6 vs. 5.9 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],2.6,193426,DB00215,Citalopram
,8451774,dem,"Both citalopram total clearance and demethylation clearance (formation of desmethylcitalopram) were significantly lower in poor metabolizers of mephenytoin compared to extensive metabolizers (median 15.2 vs. 27.3 and 2.6 vs. 5.9 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],5.9,193427,DB00215,Citalopram
,8451774,dem,"The demethylation clearance of desmethylcitalopram was significantly lower in sparteine poor metabolizers compared to extensive metabolizers (0.3 vs. 2.4 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],0.3,193428,DB00215,Citalopram
,8451774,dem,"The demethylation clearance of desmethylcitalopram was significantly lower in sparteine poor metabolizers compared to extensive metabolizers (0.3 vs. 2.4 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],2.4,193429,DB00215,Citalopram
,8451774,clearance,"The demethylation clearance of desmethylcitalopram was significantly lower in sparteine poor metabolizers compared to extensive metabolizers (0.3 vs. 2.4 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],0.3,193430,DB00215,Citalopram
,8451774,clearance,"The demethylation clearance of desmethylcitalopram was significantly lower in sparteine poor metabolizers compared to extensive metabolizers (0.3 vs. 2.4 L/h, respectively).",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),[l] / [h],2.4,193431,DB00215,Citalopram
,8451774,metabolic ratio,"During administration of citalopram, there was a modest increase in sparteine metabolic ratio from median 0.31 to 0.80 in extensive metabolizers of sparteine, whereas the mephenytoin S/R ratio was unaltered during citalopram treatment.",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),,0.31,193432,DB00215,Citalopram
,8451774,metabolic ratio,"During administration of citalopram, there was a modest increase in sparteine metabolic ratio from median 0.31 to 0.80 in extensive metabolizers of sparteine, whereas the mephenytoin S/R ratio was unaltered during citalopram treatment.",Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451774/),,0.80,193433,DB00215,Citalopram
,6939299,Systemic,"Systemic and apparent oral clearance estimates (mean 0.42 l plasma/min.) were similar, indicating roughly complete systemic availability.",The kinetics of citalopram: single and multiple dose studies in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6939299/),[l·plasma] / [min],0.42,194329,DB00215,Citalopram
,6939299,apparent oral clearance,"Systemic and apparent oral clearance estimates (mean 0.42 l plasma/min.) were similar, indicating roughly complete systemic availability.",The kinetics of citalopram: single and multiple dose studies in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6939299/),[l·plasma] / [min],0.42,194330,DB00215,Citalopram
,6939299,total volume of distribution,The data from the intravenous test revealed two compartment kinetics; the total volume of distribution was estimated to about 1150 l and that of the central compartment to 175 l.,The kinetics of citalopram: single and multiple dose studies in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6939299/),l,1150,194331,DB00215,Citalopram
,6939299,total volume of distribution,The data from the intravenous test revealed two compartment kinetics; the total volume of distribution was estimated to about 1150 l and that of the central compartment to 175 l.,The kinetics of citalopram: single and multiple dose studies in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6939299/),l,175,194332,DB00215,Citalopram
,6939299,half-life of elimination,Upon repeated administration steady-state conditions were generally achieved after one week in agreement with the 33 hrs half-life of elimination.,The kinetics of citalopram: single and multiple dose studies in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6939299/),h,33,194333,DB00215,Citalopram
,26950553,ΔΔQTcI,"The maximum upper bound 95% confidence interval for the ΔΔQTcI of quetiapine IR and escitalopram was 13.7 and 10.5 ms, with mean estimates of 10.2 and 6.9 ms, respectively.","A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26950553/),ms,13.7,198581,DB00215,Citalopram
,26950553,ΔΔQTcI,"The maximum upper bound 95% confidence interval for the ΔΔQTcI of quetiapine IR and escitalopram was 13.7 and 10.5 ms, with mean estimates of 10.2 and 6.9 ms, respectively.","A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26950553/),ms,10.5,198582,DB00215,Citalopram
,26950553,ΔΔQTcI,"The maximum upper bound 95% confidence interval for the ΔΔQTcI of quetiapine IR and escitalopram was 13.7 and 10.5 ms, with mean estimates of 10.2 and 6.9 ms, respectively.","A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26950553/),ms,10.2,198583,DB00215,Citalopram
,26950553,ΔΔQTcI,"The maximum upper bound 95% confidence interval for the ΔΔQTcI of quetiapine IR and escitalopram was 13.7 and 10.5 ms, with mean estimates of 10.2 and 6.9 ms, respectively.","A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26950553/),ms,6.9,198584,DB00215,Citalopram
,8384945,Absolute bioavailability,"Absolute bioavailability of citalopram is almost 100%, whereas it is likely that the other compounds undergo (substantial) first-pass metabolism.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,100,201450,DB00215,Citalopram
,8384945,Apparent oral clearance,"Apparent oral clearance values after single doses range from 26 L/h (citalopram) to 167 L/h (paroxetine), while after multiple doses oral clearance is markedly reduced, particularly for fluoxetine and paroxetine.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),[l] / [h],26,201451,DB00215,Citalopram
,8384945,Apparent oral clearance,"Apparent oral clearance values after single doses range from 26 L/h (citalopram) to 167 L/h (paroxetine), while after multiple doses oral clearance is markedly reduced, particularly for fluoxetine and paroxetine.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),[l] / [h],167,201452,DB00215,Citalopram
> or =,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,95,201453,DB00215,Citalopram
,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,77,201454,DB00215,Citalopram
,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,50,201455,DB00215,Citalopram
,8384945,half-lives,"The half-lives of fluvoxamine, paroxetine, sertraline and citalopram are approximately 1 day.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,1,201456,DB00215,Citalopram
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,2,201457,DB00215,Citalopram
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,6,201458,DB00215,Citalopram
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,7 to 15,201459,DB00215,Citalopram
,12454950,binding potential (BP),[(11)C]-DASB binding potential (BP) values ranged from about 0.2 in the neocortex to 2.2 in the midbrain.,"[11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454950/),,0.2,202649,DB00215,Citalopram
,12454950,binding potential (BP),[(11)C]-DASB binding potential (BP) values ranged from about 0.2 in the neocortex to 2.2 in the midbrain.,"[11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454950/),,2.2,202650,DB00215,Citalopram
,19011672,AUCS/R ratio,The kinetic disposition of CITA was enantioselective in rats (AUCS/R ratio = 0.4).,"Influence of quinidine, fluvoxamine, and ketoconazole on the enantioselective pharmacokinetics of citalopram in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19011672/),,0.4,205323,DB00215,Citalopram
,19653973,C(max),"After ingestion of venlafaxine, the C(max) values were 36 +/- 6 ng/mL and 52 +/- 8 ng/mL in the brand-name and generic groups, respectively.",Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19653973/),[ng] / [ml],36,205895,DB00215,Citalopram
,19653973,C(max),"After ingestion of venlafaxine, the C(max) values were 36 +/- 6 ng/mL and 52 +/- 8 ng/mL in the brand-name and generic groups, respectively.",Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19653973/),[ng] / [ml],52,205896,DB00215,Citalopram
,22628062,Cmax,"Mean±Standard deviation (SD) Cmax values were 18.89±5.06 ng/mL and 18.45±5.05 ng/mL for reference and test, respectively.",Bioequivalence of two formulations of escitalopram. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22628062/),[ng] / [ml],18.89,209730,DB00215,Citalopram
,22628062,Cmax,"Mean±Standard deviation (SD) Cmax values were 18.89±5.06 ng/mL and 18.45±5.05 ng/mL for reference and test, respectively.",Bioequivalence of two formulations of escitalopram. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22628062/),[ng] / [ml],18.45,209731,DB00215,Citalopram
,22628062,AUClast,AUClast was 577.16±196.20 ng · h/mL after the administration of the reference and 577.69±220.88 ng · h/mL for the test.,Bioequivalence of two formulations of escitalopram. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22628062/),[h·ng] / [ml],577.16,209732,DB00215,Citalopram
,22628062,AUClast,AUClast was 577.16±196.20 ng · h/mL after the administration of the reference and 577.69±220.88 ng · h/mL for the test.,Bioequivalence of two formulations of escitalopram. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22628062/),[h·ng] / [ml],577.69,209733,DB00215,Citalopram
,22628062,AUCinf,AUCinf was 595.66±203.80 ng · h/mL after the administration of the reference 596.19±235.47 ng · h/mL for the test.,Bioequivalence of two formulations of escitalopram. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22628062/),[h·ng] / [ml],595.66,209734,DB00215,Citalopram
,22628062,AUCinf,AUCinf was 595.66±203.80 ng · h/mL after the administration of the reference 596.19±235.47 ng · h/mL for the test.,Bioequivalence of two formulations of escitalopram. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22628062/),[h·ng] / [ml],596.19,209735,DB00215,Citalopram
,23981149,absorption rate constant (ka ),"The estimated population absorption rate constant (ka ), clearance (CL/F) and volume of distribution (Vd/F) in Chinese healthy subjects are 0.64 L/h, 12.7 L/h and 705 L, respectively.",Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23981149/),[l] / [h],0.64,212910,DB00215,Citalopram
,23981149,clearance (CL/F),"The estimated population absorption rate constant (ka ), clearance (CL/F) and volume of distribution (Vd/F) in Chinese healthy subjects are 0.64 L/h, 12.7 L/h and 705 L, respectively.",Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23981149/),[l] / [h],12.7,212911,DB00215,Citalopram
,23981149,volume of distribution (Vd/F),"The estimated population absorption rate constant (ka ), clearance (CL/F) and volume of distribution (Vd/F) in Chinese healthy subjects are 0.64 L/h, 12.7 L/h and 705 L, respectively.",Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23981149/),l,705,212912,DB00215,Citalopram
,23981149,bioavailability,"The 90% confidence interval of CIT bioavailability obtained from NCA and PPK model were 96.4-105.4% and 92.5-103.4%, respectively.",Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23981149/),%,96.4-105.4,212913,DB00215,Citalopram
,23981149,bioavailability,"The 90% confidence interval of CIT bioavailability obtained from NCA and PPK model were 96.4-105.4% and 92.5-103.4%, respectively.",Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23981149/),%,92.5-103.4,212914,DB00215,Citalopram
,29079874,t 1/2,Pharmacokinetic in vivo investigation showed a rapid absorption of EMD386088 (2.5 and 5 mg/kg) with t 1/2 = 67 min (t max = 5 min).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),min,67,216604,DB00215,Citalopram
,29079874,t max,Pharmacokinetic in vivo investigation showed a rapid absorption of EMD386088 (2.5 and 5 mg/kg) with t 1/2 = 67 min (t max = 5 min).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),min,5,216605,DB00215,Citalopram
,29079874,volume of distribution (V d/F,Large volume of distribution (V d/F = 102 L/kg) indicated its penetration into peripheral compartments.,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),[l] / [kg],102,216606,DB00215,Citalopram
,29079874,C max,The most active coadministration of EMD386088 (2.5 mg/kg) with imipramine (15 mg/kg) resulted in slower absorption of the compound (C max = 60 min) and decrease in the volume of distribution (V d/F = 32.2 L/kg).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),min,60,216607,DB00215,Citalopram
,29079874,volume of distribution (V d/F,The most active coadministration of EMD386088 (2.5 mg/kg) with imipramine (15 mg/kg) resulted in slower absorption of the compound (C max = 60 min) and decrease in the volume of distribution (V d/F = 32.2 L/kg).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),[l] / [kg],32.2,216608,DB00215,Citalopram
,29079874,brain/plasma ratio,EMD386088 penetrates the blood-brain barrier with a high brain/plasma ratio of about 19 (2.5 mg/kg) and 7.5 for coadministration with imipramine.,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),,19,216609,DB00215,Citalopram
,29079874,brain/plasma ratio,EMD386088 penetrates the blood-brain barrier with a high brain/plasma ratio of about 19 (2.5 mg/kg) and 7.5 for coadministration with imipramine.,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),,7.5,216610,DB00215,Citalopram
,29079874,IC 50,"EMD386088 did not influence on CYP3A4 activity, and it has been classified as a very weak CYP2D6 inhibitor (IC 50 = 2.25 μM).","Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),μM,2.25,216611,DB00215,Citalopram
,26611790,metabolic clearance,"Without accounting for any patient-specific covariates, the population estimate of the metabolic clearance of citalopram was 8.6 (R-citalopram) and 14 L/h (S-citalopram).",A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26611790/),[l] / [h],8.6,218531,DB00215,Citalopram
,26611790,metabolic clearance,"Without accounting for any patient-specific covariates, the population estimate of the metabolic clearance of citalopram was 8.6 (R-citalopram) and 14 L/h (S-citalopram).",A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26611790/),[l] / [h],14,218532,DB00215,Citalopram
,26611790,clearance,The population estimate of the clearance of desmethylcitalopram was 23.8 (R-Dcit) and 38.5 L/h (S-Dcit).,A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26611790/),[l] / [h],23.8,218533,DB00215,Citalopram
,26611790,clearance,The population estimate of the clearance of desmethylcitalopram was 23.8 (R-Dcit) and 38.5 L/h (S-Dcit).,A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26611790/),[l] / [h],38.5,218534,DB00215,Citalopram
,26611790,metabolic clearance,A significant difference in the metabolic clearance of R-citalopram between males and females (13 vs 9.05 L/h) was identified in this analysis.,A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26611790/),[l] / [h],13,218535,DB00215,Citalopram
,26611790,metabolic clearance,A significant difference in the metabolic clearance of R-citalopram between males and females (13 vs 9.05 L/h) was identified in this analysis.,A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26611790/),[l] / [h],9.05,218536,DB00215,Citalopram
,10844134,steady-state plasma concentrations,"Using an infusion concentration of 50 mg/ml citalopram, steady-state plasma concentrations of approximately 0.3 mcM citalopram were maintained for 15 days.",Desensitisation of 5-HT autoreceptors upon pharmacokinetically monitored chronic treatment with citalopram. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10844134/),mcM,0.3,218902,DB00215,Citalopram
,11214779,renal clearance,"There were no significant differences between the two groups in any of the pharmacokinetic parameters with the exception of the renal clearance of citalopram, which was significantly lower in the renal failure group than in the control group (1.70 ml/min versus 66.2 ml/min, P<0.001).",Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214779/),[ml] / [min],1.70,224704,DB00215,Citalopram
,11214779,renal clearance,"There were no significant differences between the two groups in any of the pharmacokinetic parameters with the exception of the renal clearance of citalopram, which was significantly lower in the renal failure group than in the control group (1.70 ml/min versus 66.2 ml/min, P<0.001).",Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214779/),[ml] / [min],66.2,224705,DB00215,Citalopram
,11214779,Oral clearance,Oral clearance of citalopram was almost identical in the two groups (452 ml/min versus 456 ml/min).,Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214779/),[ml] / [min],452,224706,DB00215,Citalopram
,11214779,Oral clearance,Oral clearance of citalopram was almost identical in the two groups (452 ml/min versus 456 ml/min).,Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214779/),[ml] / [min],456,224707,DB00215,Citalopram
,9366029,serum t1/2,"For (-)-(R)- and (+)-(S)-citalopram, respectively, the serum t1/2 averaged 47 +/- 11 and 35 +/- 4 h and AUCss averaged 4,193 +/- 1,118 h.nmol/l and 2,562 +/- 1,190 h.nmol/l.",Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9366029/),h,47,226506,DB00215,Citalopram
,9366029,serum t1/2,"For (-)-(R)- and (+)-(S)-citalopram, respectively, the serum t1/2 averaged 47 +/- 11 and 35 +/- 4 h and AUCss averaged 4,193 +/- 1,118 h.nmol/l and 2,562 +/- 1,190 h.nmol/l.",Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9366029/),h,35,226507,DB00215,Citalopram
,9366029,AUCss,"For (-)-(R)- and (+)-(S)-citalopram, respectively, the serum t1/2 averaged 47 +/- 11 and 35 +/- 4 h and AUCss averaged 4,193 +/- 1,118 h.nmol/l and 2,562 +/- 1,190 h.nmol/l.",Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9366029/),[h·nM] / [l],"4,193",226508,DB00215,Citalopram
,9366029,AUCss,"For (-)-(R)- and (+)-(S)-citalopram, respectively, the serum t1/2 averaged 47 +/- 11 and 35 +/- 4 h and AUCss averaged 4,193 +/- 1,118 h.nmol/l and 2,562 +/- 1,190 h.nmol/l.",Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9366029/),[h·nM] / [l],"2,562",226509,DB00215,Citalopram
,16289706,extraction recoveries,"The extraction recoveries for ropinirole and internal standard were 90.45 and 65.42%, respectively.",Rapid and sensitive liquid chromatography-mass spectrometry method for determination of ropinirole in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16289706/),%,90.45,229356,DB00215,Citalopram
,16289706,extraction recoveries,"The extraction recoveries for ropinirole and internal standard were 90.45 and 65.42%, respectively.",Rapid and sensitive liquid chromatography-mass spectrometry method for determination of ropinirole in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16289706/),%,65.42,229357,DB00215,Citalopram
,16765010,recovery,"Under optimized conditions, the mean recovery was 86.6%.",High performance liquid chromatography - tandem mass spectrometric determination of cyclovirobuxine D in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16765010/),%,86.6,229420,DB00215,Citalopram
,23919086,flux,"With regard to the pharmacokinetic parameters of citalopram, the flux required for the transdermal delivery system was about 1280 μg per hour.",Effect of microemulsions on transdermal delivery of citalopram: optimization studies using mixture design and response surface methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23919086/),[μg] / [h],1280,237738,DB00215,Citalopram
,23919086,flux rates,"The microemulsions loaded with citalopram 3% and 10% showed respective flux rates of 179.6 μg/cm(2) and 513.8 μg/cm(2) per hour, indicating that the study formulation could provide effective therapeutic concentrations over a practical application area.",Effect of microemulsions on transdermal delivery of citalopram: optimization studies using mixture design and response surface methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23919086/),[μg] / [cm(2],179.6,237739,DB00215,Citalopram
,23919086,flux rates,"The microemulsions loaded with citalopram 3% and 10% showed respective flux rates of 179.6 μg/cm(2) and 513.8 μg/cm(2) per hour, indicating that the study formulation could provide effective therapeutic concentrations over a practical application area.",Effect of microemulsions on transdermal delivery of citalopram: optimization studies using mixture design and response surface methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23919086/),[μg] / [cm(2)·h],513.8,237740,DB00215,Citalopram
,20352615,flow rate,"Chromatographic separation was operated with 0.2% formic acid:acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a Symmetry Shield RP(18) column with a total run time of 3.0 min.",A highly sensitive LC-MS/MS method for the determination of S-citalopram in rat plasma: application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20352615/),[ml] / [min],0.50,241568,DB00215,Citalopram
,20352615,total run time,"Chromatographic separation was operated with 0.2% formic acid:acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a Symmetry Shield RP(18) column with a total run time of 3.0 min.",A highly sensitive LC-MS/MS method for the determination of S-citalopram in rat plasma: application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20352615/),min,3.0,241569,DB00215,Citalopram
,24071566,t(max),"LY2456302 exhibits canonical pharmacokinetic properties that are favorable for clinical development, with rapid absorption (t(max): 1-2 h) and good oral bioavailability (F = 25%).","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),h,1-2,241686,DB00215,Citalopram
,24071566,oral bioavailability (F,"LY2456302 exhibits canonical pharmacokinetic properties that are favorable for clinical development, with rapid absorption (t(max): 1-2 h) and good oral bioavailability (F = 25%).","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),%,25,241687,DB00215,Citalopram
,24071566,ED₅₀,"Oral LY2456302 administration selectively and potently occupied central kappa opioid receptors in vivo (ED₅₀ = 0.33 mg/kg), without evidence of mu or delta receptor occupancy at doses up to 30 mg/kg.","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),[mg] / [kg],0.33,241688,DB00215,Citalopram
,10574684,Cmax,"The respective pharmacokinetic parameters were: Cmax = 214+/-41 and 246+/-69 nmol eq./litre, Tmax = 3 and 2 h, AUC = 18289+/-2959 and 14537+/-2883 nmol eq.",Metabolism and excretion of citalopram in man: identification of O-acyl- and N-glucuronides. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10574684/),[eq·nM] / [l],214,242791,DB00215,Citalopram
,10574684,Cmax,"The respective pharmacokinetic parameters were: Cmax = 214+/-41 and 246+/-69 nmol eq./litre, Tmax = 3 and 2 h, AUC = 18289+/-2959 and 14537+/-2883 nmol eq.",Metabolism and excretion of citalopram in man: identification of O-acyl- and N-glucuronides. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10574684/),[eq·nM] / [l],246,242792,DB00215,Citalopram
,10574684,Tmax,"The respective pharmacokinetic parameters were: Cmax = 214+/-41 and 246+/-69 nmol eq./litre, Tmax = 3 and 2 h, AUC = 18289+/-2959 and 14537+/-2883 nmol eq.",Metabolism and excretion of citalopram in man: identification of O-acyl- and N-glucuronides. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10574684/),h,3,242793,DB00215,Citalopram
,10574684,Tmax,"The respective pharmacokinetic parameters were: Cmax = 214+/-41 and 246+/-69 nmol eq./litre, Tmax = 3 and 2 h, AUC = 18289+/-2959 and 14537+/-2883 nmol eq.",Metabolism and excretion of citalopram in man: identification of O-acyl- and N-glucuronides. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10574684/),h,2,242794,DB00215,Citalopram
,10574684,AUC,"The respective pharmacokinetic parameters were: Cmax = 214+/-41 and 246+/-69 nmol eq./litre, Tmax = 3 and 2 h, AUC = 18289+/-2959 and 14537+/-2883 nmol eq.",Metabolism and excretion of citalopram in man: identification of O-acyl- and N-glucuronides. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10574684/),eq·nM,18289,242795,DB00215,Citalopram
,10574684,AUC,"The respective pharmacokinetic parameters were: Cmax = 214+/-41 and 246+/-69 nmol eq./litre, Tmax = 3 and 2 h, AUC = 18289+/-2959 and 14537+/-2883 nmol eq.",Metabolism and excretion of citalopram in man: identification of O-acyl- and N-glucuronides. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10574684/),eq·nM,14537,242796,DB00215,Citalopram
,10574684,t1/2,"h/litre, and t1/2 = 90.2+/-22.5 and 79.5 +/- 14.9 h respectively.",Metabolism and excretion of citalopram in man: identification of O-acyl- and N-glucuronides. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10574684/),h,90.2,242797,DB00215,Citalopram
,10574684,t1/2,"h/litre, and t1/2 = 90.2+/-22.5 and 79.5 +/- 14.9 h respectively.",Metabolism and excretion of citalopram in man: identification of O-acyl- and N-glucuronides. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10574684/),h,79.5,242798,DB00215,Citalopram
,12968986,CT half-life,"Based on two time points, this subject had a very long CT half-life of 95 h.",Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968986/),h,95,246479,DB00215,Citalopram
,20040133,flow rate,"Chromatographic separation was performed on a CN column (250 mm x 4.6 mm, 5 microm) with a mobile phase of methanol/40 mM ammonium acetate/formic acid (950:45:5, v/v/v) at the flow rate of 1.0 mL/min.","Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the rapid simultaneous quantification of aconitine, mesaconitine, and hypaconitine in rat plasma after oral administration of Sini decoction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20040133/),[ml] / [min],1.0,255726,DB00215,Citalopram
,17542353,peak plasma concentration Cmax,"The average bioavailability and pharmacokinetic parameters of the two citalopram tablets were as follows: peak plasma concentration Cmax was 35.0 +/- 10.04 ng/ml and 33.4 +/-7.80 ng/ml for Lecital and Cipramil, respectively.",Pharmacokinetic comparison of two 40 mg tablet formulations of citalopram using a new amperometric detection technique. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17542353/),[ng] / [ml],35.0,257221,DB00215,Citalopram
,17542353,peak plasma concentration Cmax,"The average bioavailability and pharmacokinetic parameters of the two citalopram tablets were as follows: peak plasma concentration Cmax was 35.0 +/- 10.04 ng/ml and 33.4 +/-7.80 ng/ml for Lecital and Cipramil, respectively.",Pharmacokinetic comparison of two 40 mg tablet formulations of citalopram using a new amperometric detection technique. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17542353/),[ng] / [ml],33.4,257222,DB00215,Citalopram
,17542353,time to peak plasma concentrations tmax,"The time to peak plasma concentrations tmax were 3.81 +/- 1.18 and 4.08 +/- 1.54 h, while the plasma half-life (t1/2) values were 54.0 +/- 7.50 and 54.7 +/- 10.6 h.",Pharmacokinetic comparison of two 40 mg tablet formulations of citalopram using a new amperometric detection technique. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17542353/),h,3.81,257223,DB00215,Citalopram
,17542353,time to peak plasma concentrations tmax,"The time to peak plasma concentrations tmax were 3.81 +/- 1.18 and 4.08 +/- 1.54 h, while the plasma half-life (t1/2) values were 54.0 +/- 7.50 and 54.7 +/- 10.6 h.",Pharmacokinetic comparison of two 40 mg tablet formulations of citalopram using a new amperometric detection technique. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17542353/),h,4.08,257224,DB00215,Citalopram
,17542353,plasma half-life (t1/2),"The time to peak plasma concentrations tmax were 3.81 +/- 1.18 and 4.08 +/- 1.54 h, while the plasma half-life (t1/2) values were 54.0 +/- 7.50 and 54.7 +/- 10.6 h.",Pharmacokinetic comparison of two 40 mg tablet formulations of citalopram using a new amperometric detection technique. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17542353/),h,54.0,257225,DB00215,Citalopram
,17542353,plasma half-life (t1/2),"The time to peak plasma concentrations tmax were 3.81 +/- 1.18 and 4.08 +/- 1.54 h, while the plasma half-life (t1/2) values were 54.0 +/- 7.50 and 54.7 +/- 10.6 h.",Pharmacokinetic comparison of two 40 mg tablet formulations of citalopram using a new amperometric detection technique. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17542353/),h,54.7,257226,DB00215,Citalopram
,17542353,area under the plasma concentration-time profiles AUCo-t,"The area under the plasma concentration-time profiles AUCo-t were 1,820 +/- 582 ng x h/ml and 1,660 +/- 510 ng x h/ml, whereas the AUC0-infinity were 2,010 +/- 663 ng x h/ml and 1,850 +/- 577 ng x h/ml for Lecital and Cipramil, respectively.",Pharmacokinetic comparison of two 40 mg tablet formulations of citalopram using a new amperometric detection technique. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17542353/),[h·ng] / [ml],"1,820",257227,DB00215,Citalopram
,17542353,area under the plasma concentration-time profiles AUCo-t,"The area under the plasma concentration-time profiles AUCo-t were 1,820 +/- 582 ng x h/ml and 1,660 +/- 510 ng x h/ml, whereas the AUC0-infinity were 2,010 +/- 663 ng x h/ml and 1,850 +/- 577 ng x h/ml for Lecital and Cipramil, respectively.",Pharmacokinetic comparison of two 40 mg tablet formulations of citalopram using a new amperometric detection technique. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17542353/),[h·ng] / [ml],"1,660",257228,DB00215,Citalopram
,17542353,AUC0-infinity,"The area under the plasma concentration-time profiles AUCo-t were 1,820 +/- 582 ng x h/ml and 1,660 +/- 510 ng x h/ml, whereas the AUC0-infinity were 2,010 +/- 663 ng x h/ml and 1,850 +/- 577 ng x h/ml for Lecital and Cipramil, respectively.",Pharmacokinetic comparison of two 40 mg tablet formulations of citalopram using a new amperometric detection technique. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17542353/),[h·ng] / [ml],"2,010",257229,DB00215,Citalopram
,17542353,AUC0-infinity,"The area under the plasma concentration-time profiles AUCo-t were 1,820 +/- 582 ng x h/ml and 1,660 +/- 510 ng x h/ml, whereas the AUC0-infinity were 2,010 +/- 663 ng x h/ml and 1,850 +/- 577 ng x h/ml for Lecital and Cipramil, respectively.",Pharmacokinetic comparison of two 40 mg tablet formulations of citalopram using a new amperometric detection technique. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17542353/),[h·ng] / [ml],"1,850",257230,DB00215,Citalopram
,20642546,oral midazolam clearance,"In a cross-over study, healthy volunteers (n = 9) phenotyped as extensive metabolizers of CYP2C19 and CYP2D6 and with an oral midazolam clearance ranging from 10.9 to 149.3 ml min(-1) kg(-1) received a single dose of racemic CITA (20 mg orally) in combination or not with omeprazole (20 mg day(-1) for 18 days).",Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20642546/),[ml] / [kg·min],10.9 to 149.3,259312,DB00215,Citalopram
,30388703,extraction recovery,"The developed methods were linear, accurate, and precise for the determination of DSV, VLX, ESP and AGT with extraction recovery of 90 ± 2.0, 98 ± 1.0, 90 ± 1.3 and 87 ± 4.3%, respectively.",Optimized bio-analytical methods development and comparative pharmacokinetic studies of four antidepressants in Egyptian population based on gender difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30388703/),%,90,264140,DB00215,Citalopram
,30388703,extraction recovery,"The developed methods were linear, accurate, and precise for the determination of DSV, VLX, ESP and AGT with extraction recovery of 90 ± 2.0, 98 ± 1.0, 90 ± 1.3 and 87 ± 4.3%, respectively.",Optimized bio-analytical methods development and comparative pharmacokinetic studies of four antidepressants in Egyptian population based on gender difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30388703/),%,98,264141,DB00215,Citalopram
,30388703,extraction recovery,"The developed methods were linear, accurate, and precise for the determination of DSV, VLX, ESP and AGT with extraction recovery of 90 ± 2.0, 98 ± 1.0, 90 ± 1.3 and 87 ± 4.3%, respectively.",Optimized bio-analytical methods development and comparative pharmacokinetic studies of four antidepressants in Egyptian population based on gender difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30388703/),%,90,264142,DB00215,Citalopram
,30388703,extraction recovery,"The developed methods were linear, accurate, and precise for the determination of DSV, VLX, ESP and AGT with extraction recovery of 90 ± 2.0, 98 ± 1.0, 90 ± 1.3 and 87 ± 4.3%, respectively.",Optimized bio-analytical methods development and comparative pharmacokinetic studies of four antidepressants in Egyptian population based on gender difference. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30388703/),%,87,264143,DB00215,Citalopram
,26650488,cerebrospinal fluid/serum ratio,"The cerebrospinal fluid/serum ratio for citalopram (total=bound+unbound concentration) varied between 0.14 and 0.86 (mean 0.35, SD 0.16).",Measuring citalopram in blood and cerebrospinal fluid: revealing a distribution pattern that differs from other antidepressants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26650488/),,0.35,272648,DB00215,Citalopram
